Acne Vulgaris – Pipeline Review, H1 2017
- Pages: 177
- Published: May 2017
- Report Code: GMDHC9230IDB
Global Markets Direct’s, ‘Acne Vulgaris – Pipeline Review, H1 2017’, provides an overview of the Acne Vulgaris pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects
The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Acne Vulgaris
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
3SBio Inc
Allergan Plc
Almirall SA
Biomar Microbial Technologies
BioPharmX Inc
Braintree Laboratories Inc
Brickell Biotech Inc
Cassiopea SpA
Cell Medica Ltd
Cellceutix Corp
Celtaxsys Inc
Common Pharma Inc
Cutanea Life Sciences Inc
Dermira Inc
ELORAC Inc
Ensol Biosciences Inc
Foamix Pharmaceuticals Ltd
Galderma SA
GlaxoSmithKline Plc
Helix BioMedix Inc
Hovione FarmaCiencia SA
Lee's Pharmaceutical Holdings Ltd
LEO Pharma A/S
Novabiotics Ltd
Novan Inc
Novartis AG
Paratek Pharmaceuticals Inc
Pfizer Inc
Phosphagenics Ltd
Photocure ASA
Promius Pharma LLC
Provectus Biopharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Sol-Gel Technologies Ltd
Sun Pharma Advanced Research Company Ltd
Valeant Pharmaceuticals International Inc
Vectura Group Plc
Vyome Biosciences Pvt Ltd
XBiotech Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.